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LETTERS
Maximizing the  
Value of Drug 
Stockpiles for  
Pandemic Influenza
To  the  Editor:  Tamiflu  (osel-
tamivir;  Roche,  Indianapolis,  IN, 
USA)  is  destined  to  be  one  of  the 
few  branded  drugs  to  develop  in-
stant street recognition because of its 
status as 1 of only 2 licensed drugs 
shown to be active against the influ-
enza A pandemic (H1N1) 2009 virus. 
Tamiflu is the major drug stockpiled 
by  governments  around  the  world 
in preparedness against an influenza 
pandemic. More than 70 governments 
have placed orders for Tamiflu, and 
at least 220 million treatment courses 
have been stockpiled since 2003 at a 
cost of $6.9 billion (1). Roche is pro-
ducing 110 million courses for the 5 
months from May to fall 2009 and 
will produce up to 36 million courses 
per month by year’s end if necessary. 
Given  the  estimated  world  popula-
tion of 6.8 billion, it is clear that, on a 
global basis, stockpiles are woefully 
inadequate. For the United Kingdom, 
official  estimates  indicate  sufficient 
stocks currently exist for half of the 
population (2).
Given the high cost of these stock-
piles, every effort should be made to 
maximize  usage  of  the  drug.  Most 
of us are aware of shelf-life assign-
ment to foods, a concept first applied 
to drugs well before its adoption by 
food manufacturers. Shelf-life exten-
sion could potentially yield significant 
cost  savings  in  the  event  stockpiled 
drugs are not required for use within 
the typical 5-year shelf life. We use 
Tamiflu as a case example to suggest 
how this could be done through care-
ful evidence-based risk assessment.
The  chemical  integrity  of  any 
medicine, including Tamiflu, is impor-
tant because decomposition may lead 
to loss of activity or formation of toxic 
products.  For  formulated  products, 
decomposition may lead to impaired 
bioavailability. As it became obvious 
that there were inadequate drug stock-
piles even in affluent countries, one of 
our authors (A.L.W.P., who had served 
as a member of the UK Committee on 
Safety  of  Medicines  [3,4])  wrote  to 
his local member of parliament (coau-
thor N.P.) to suggest that the govern-
ment institute a program to extend the 
shelf life of drug stockpiles. A.L.W.P. 
argued that the relatively minor devel-
opment work necessary to implement 
a shelf-life extension program would 
be highly cost-effective. The UK De-
partment of Health then initiated a col-
laboration with Roche to extend the 
shelf life of Tamiflu. On May 8, 2009, 
the European Medicines Agency inde-
pendently advised that new batches of 
Tamiflu would have a shelf life of 7 
years instead of only 5 years (5).
Oseltamivir  is  a  prodrug  that 
needs  metabolic  activation  (Figure) 
(6).  Prodrugs  are  used  typically  to 
reduce toxicity caused by functional 
groups such as the carboxylate ion, to 
alter release properties (e.g., prolong-
ing action of antipsychotic agents), or 
to improve absorption (bioavailability) 
by making the drug more lipophilic.
Oseltamivir  carboxylic  acid  has 
poor bioavailability; <5% orally com-
pared to 80% for oseltamivir, the par-
ent  drug  (7). The  carboxylate  is  the 
only major metabolite and the princi-
pal degradation product (7,8). There-
fore, with poor storage the major risk 
is  reduced  activity  through  reduced 
absorption  rather  than  formation  of 
toxic by-products.
Health  agencies  also  stockpile 
other drugs (9), most notably antimi-
crobial drugs and vaccines. Shelf-life 
extension would need to be assessed 
on  a  product-by-product  basis.  For 
example, antimicrobial drugs are of-
ten quite unstable and the toxicologic 
implications are less clear; some evi-
dence  suggests  that  allergenic  poly-
mers could be formed while the drugs 
are in storage. On the positive side, an-
timicrobial drugs are considerably less 
expensive than neuramidase inhibitors 
such as Tamiflu, making antimicrobial 
stockpiles less costly to replenish. 
Products with more complicated 
delivery systems, such as zanamivir in 
inhalers, would require more valida-
tion. For biological products in com-
plex  formulations  such  as  vaccines, 
stability validation may not be cost-
effective.
Given the high costs involved in 
maintaining adequate drug stockpiles, 
attempts should be made to optimize 
the value of drugs; shelf-life extension 
is one of the easiest and most cost-ef-
fective ways of doing this. We suggest 
that governments undertake a system-
atic  program  for  iterative  shelf-life 
extension, ideally cooperatively. The 
considerable  financial  savings  could 
mitigate drug shortages of expensive 
antiviral drugs. The chemical profile of 
oseltamivir and its degradation path-
way suggest that extending the shelf 
life of Tamiflu to >20 years should be 
feasible. Storage in dry airtight con-
tainers should be able to maintain the 
integrity of the product for >7 years. 
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Figure. Metabolic activation of oseltamivir to carboxylic acid.LETTERS
During a pandemic, when supplies are 
unavailable, the balance of benefit to 
harm would favor using the expired 
product. 
The 1918 influenza pandemic is 
estimated  to  have  killed  50  million 
persons worldwide (10), many in de-
veloping  countries.  By  better  safe-
guarding  available  drug  stockpiles, 
more drugs could be made available to 
poorer countries that have few drugs 
stockpiled. 
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Intrafamilial  
Transmission of  
Methicillin-Resistant   
Staphylococcus  
aureus1
To  the  Editor:  Community-ac-
quired methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) infection 
was first described in our region over 
15 years ago (1). More recently, CA-
MRSA has become a global concern 
and is now a common cause of skin 
and soft tissue infections in the Unit-
ed States (2). An association between 
severe  CA-MRSA  infection  (e.g., 
necrotizing fasciitis and pneumonia) 
and the synergohymenotrophic exo-
toxin  Panton-Valentine  leukocidin 
(PVL) has been made (3,4). Reports 
have  documented  CA-MRSA  trans-
mission among household members; 
however, most cases have been mild 
or moderate infections or asymptom-
atic colonization (5–7). We describe 
intrafamilial transmission of a PVL-
containing  CA-MRSA  clone  com-
mon  in Australia  (ST30-MRSA-IV) 
between  a  nurse  who  experienced 
recurrent abscesses and her husband, 
who died of severe pneumonia. 
 In July 2006, a 61-year-old pre-
viously healthy nurse (Mrs A) sought 
treatment  for  an  infected  seborrheic 
cyst of the scalp. Culture of pus yield-
ed MRSA that was susceptible to clin-
damycin.  She  was  treated  with  oral 
clindamycin. After  resolution  of  the 
infection, topical MRSA decoloniza-
tion therapy with 3% hexachlorophane 
body  wash  (daily),  20%  cetrimide 
shampoo (3×/wk), and 2% mupirocin 
nasal  ointment  (3×/d)  was  adminis-
tered for 10 days, as per our institu-
tional  protocol  for  MRSA-colonized 
healthcare  workers.  Subsequently, 
MRSA  surveillance  swabs  from  the 
nose, throat, and scalp obtained week-
ly for 10 weeks and cultured on selec-
tive MRSA chromogenic agar and in 
selective broth enrichment media were 
negative.  Household  members  were 
not screened for MRSA colonization.
Six months later, in January 2007, 
the  patient’s  husband  (Mr A),  a  60-
year-old  smoker  who  was  her  only 
household contact, was admitted with 
a 1-day history of dyspnea, pleuritic 
chest pain, cough with sputum, fever, 
vomiting, and diarrhea. On admission, 
he was unwell, with tachycardia (pulse 
rate  132  bpm),  hypotension  (95/60 
mm Hg), tachypnea (40 breaths/min), 
and hypoxia (oxygen saturation 93% 
on 15 L O2/min). A chest radiograph 
showed bilateral infiltrates and a right 
pleural  effusion.  He  was  diagnosed 
with community-acquired pneumonia 
and  treated  with  intravenous  ceftri-
axone  and  azithromycin  as  per  local 
protocol.  However,  within  12  hours, 
his condition deteriorated, necessitat-
ing admission to the intensive care unit 
for ventilation and inotropic support. 
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1Results  presented  in  part  at  the 
Australasian Society for Infectious Diseases 
Annual Scientific Meeting, Sunshine Coast, 
Queensland, Australia, 2008 April 2–5. 